Search Browse Earnings

Lyell Immunopharma, Inc. — SlamSEC

Lyell Immunopharma, Inc.

Nasdaq:LYEL

Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$84.7M

+695.1% YoY

FY 2024

Adj. EBITDA

-$169.0M

-199.6% margin

FY 2024

Net Income

-$183.1M

-216.2% margin

FY 2024

EPS (Diluted)

-$0.74

FY 2024

Stock Price

$25.36

+12.9%

2026-03-09

52W Range

$7.65 – $45.00

P/E Ratio

-34.3x

Market Cap

$538.1M

Cash

$123.6M

FY 2024

Total Debt

—

Net Cash

$123.6M

FY 2024

Enterprise Value

$414.5M

Debt / EBITDA

0.7x

FY 2024

EV / EBITDA

-2.5x

Employees

—